The estimated Net Worth of Partners Viii, L.P.Blair Ja... is at least $269 Миллион dollars as of 21 October 2014. Partners Ja owns over 248,159 units of Glaukos stock worth over $268,763,521 and over the last 10 years Partners sold GKOS stock worth over $0.
Partners has made over 2 trades of the Glaukos stock since 2014, according to the Form 4 filled with the SEC. Most recently Partners bought 248,159 units of GKOS stock worth $2,729,749 on 21 October 2014.
The largest trade Partners's ever made was buying 248,159 units of Glaukos stock on 21 October 2014 worth over $2,729,749. On average, Partners trades about 78,979 units every 16 days since 2014. As of 21 October 2014 Partners still owns at least 2,141,542 units of Glaukos stock.
You can see the complete history of Partners Ja stock trades at the bottom of the page.
Over the last 11 years, insiders at Glaukos have traded over $300,254,118 worth of Glaukos stock and bought 17,376 units worth $317,262 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Gilbert H Kliman и Jonathan Silverstein. On average, Glaukos executives and independent directors trade stock every 25 days with the average trade being worth of $8,240,079. The most recent stock trade was executed by Gilbert H Kliman on 9 September 2024, trading 3,000 units of GKOS stock currently worth $96,000.
glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde
Glaukos executives and other stock owners filed with the SEC include: